Date: 2015-12-09
Type of information: Resignation
Compound:
Company: The Medicines Company (USA - NJ)
Therapeutic area:
Type agreement: resignation
Action mechanism:
Disease:
Details: * On December 9, 2015, The Medicines Company announced that Glenn Sblendorio, President and Chief Financial Officer, will retire from the company effective March 31, 2016. As of January 1, 2016, Mr. Sblendorio will be relinquishing his seat on the Board of Directors and his operational responsibilities will be assumed by others within the company. William O’Connor, Senior Vice President & Chief Accounting Officer, who has been with The Medicines Company since 2006, will succeed Mr. Sblendorio as Chief Financial Officer. Mr. Sblendorio will continue as a strategic advisor to Clive Meanwell, MD, PhD, Chief Executive Officer of the company, until the end of March. Mr. Sblendorio has been a Director at The Medicines Company since July 2011 and has been the company’s Chief Financial Officer and President since February 2012. Prior to joining the company, Mr. Sblendorio was Executive Vice President and Chief Financial Officer of Eyetech Pharmaceuticals, Inc. and the Chief Executive Officer and Managing Director of MPM Capital Advisors, LLC, an investment bank specializing in healthcare related transactions. His pharmaceutical experience also includes 12 years at Hoffmann-LaRoche, Inc., a pharmaceutical company, in a variety of senior financial positions. Mr. Sblendorio currently serves as a Director of Amicus Therapeutics, Inc., a biopharmaceutical company, Intercept Pharmaceuticals, Inc., a biopharmaceutical company and Ophthotech Corporation, an ophthalmology company.
Financial terms:
Latest news:
